Dementia Diagnosis Takes an Average of 3 Years: New Data
The average time to diagnosis (TTD) of dementia was 3.5 years in a new meta-analysis, with younger age at onset and having frontotemporal dementia consistently associated with even longer diagnostic intervals.
METHODOLOGY:
This systematic review and meta-analysis used data from 13 cohort studies published up to December 2024. More than 30,000 patients with a diagnosis of dementia were included, with the age at onset ranging between 54 and 93 years.
TTD was defined as the interval between the onset of symptoms, rated by family carers or patients using interviews or medical records, and the final diagnosis.
TAKEAWAY:
A meta-analysis of 10 studies showed the average TTD across all types of dementia was 3.5 years (95% CI, 2.7-4.3), with moderate-quality evidence.
An analysis of six studies showed that the average TTD of young-onset dementia was 4.1 years (95% CI, 3.4-4.9), also with moderate-quality evidence.
An analysis by dementia type showed consistently longer TTDs for young-onset Alzheimer's disease (TTD, 4.0 years; 95% CI, 2.7-5.2) and frontotemporal dementia (TTD, 4.7 years; 95% CI, 3.0-6.4).
In contrast, TTD in late-onset dementia was 2.9 years (95% CI, 2.6-3.2) in analysis of two studies.
IN PRACTICE:
'Timely diagnosis of dementia remains a major global challenge, shaped by a complex set of factors, and specific healthcare strategies are urgently needed to improve it,' lead investigator Vasiliki Orgeta, PhD, Division of Psychiatry, University College London, London, England, said in a press release.
'Clinician training is critical to improve early recognition and referral, along with access to early intervention and individualized support, so that people with dementia and their families can get the help they need,' Orgeta added.
SOURCE:
The study was published online on July 27 in International Journal of Geriatric Psychiatry.
LIMITATIONS:
Definitions of TTD varied across studies, with different methods used to assess the first symptoms of dementia. The current meta-analysis did not assess factors affecting TTD. Additionally, individuals with severe dementia may not have accurately remembered when they first experienced symptoms, potentially introducing a recall bias. The findings were also not applicable to low- and medium-income countries.
DISCLOSURES:
The investigators reported having no relevant conflicts of interest.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Is Novo Nordisk Stock a Buy, Sell, or Hold Before Q2 Earnings?
Danish pharmaceutical giant Novo Nordisk A/S (NVO) is facing serious headwinds. After enjoying a strong run fueled by demand for its obesity treatments, the obesity drug pioneer is now under pressure from rising competition, particularly from Eli Lilly's (LLY) weight-loss drugs, as well as trial setbacks for its next-generation therapies. In fact, things took a sharp turn on July 29, when the company cut its full-year sales growth guidance for the second time in just three months and named a new CEO. The market response was swift and brutal, with NVO shares plunging over 21% in a single day. Now, with second-quarter earnings just around the corner on Aug. 6, does Novo Nordisk's recent plunge present a golden buying opportunity, or is it a clear signal to keep your distance? More News from Barchart Dear Nvidia Stock Fans, Mark Your Calendars for August 27 Options Traders Expected Palantir Stock's Tamest Earnings Reaction in a Year. Did They Get It Right? Tesla Gains on Elon Musk's New Pay Package. Is TSLA Stock a Buy? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! About Novo Nordisk Stock Best known for its blockbuster weight-loss drugs Ozempic and Wegovy, Novo Nordisk is a global healthcare leader with a long-standing focus on chronic disease. Founded in 1923 and headquartered in Denmark, the company has built a strong foundation in diabetes care while expanding its reach into obesity and other severe health conditions. The company commands a market capitalization of about $217.9 billion. While Novo Nordisk has been a trailblazer in the obesity drug market, its stock has hit a rough patch. Softer demand for its blockbuster drugs, combined with intensifying competition in the weight-loss space, has taken a toll on investor sentiment. The stock has tumbled a staggering 66% from its 52-week high of $139.74 reached in August 2024, and it's currently down 44.7% year-to-date (YTD). In stark contrast, the broader S&P 500 Index ($SPX) has managed to notch a gain of approximately 7.1% over the same period, while its rival Eli Lilly has seen only a marginal drop so far this year, highlighting just how far Novo has fallen out of favor with the market. Given its underwhelming price action, Novo Nordisk stock is starting to look like a value play. Currently trading at just 12.5 times forward earnings, it's priced well below the sector median of 16.87x, and dramatically lower than its own five-year average of 30.92x. Novo Nordisk's Q1 Earnings Snapshot In early May, Novo Nordisk posted a solid first-quarter earnings report for fiscal 2025, but the shine was dulled by a cautious outlook. Total revenue climbed 19% year-over-year (YOY) to 78.1 billion Danish kroner, powered by a massive 85% surge in Wegovy sales, which hit 17.4 billion Danish kroner. Ozempic also continued to perform, with sales rising 18% to 32.7 billion Danish kroner. Profits also impressed, with net profit climbing 14% to 29 billion Danish kroner, while operating profit increased 22% to 38.8 billion Danish kroner. But despite these promising numbers, Novo trimmed its full-year sales growth and operating profit growth guidance, citing 'lower-than-planned penetration of branded GLP-1 treatments in the US.' The company pointed to the growing presence of U.S. compounding pharmacies, which have been legally producing copycat versions of Wegovy and Ozempic under an FDA-approved exemption for addressing drug shortages. That growing parallel market has begun to chip away at Novo's momentum. On a more promising note, the company completed its REDEFINE 2 trial during the quarter, with its next-generation drug CagriSema delivering an impressive 15.7% weight loss in patients with obesity or overweight conditions and type 2 diabetes. Novo plans to file for its first regulatory approval in early 2026, potentially marking the next significant chapter in its obesity pipeline. Novo Nordisk Slashes Guidance Again and Names New CEO On July 29, Novo Nordisk held a conference call that left investors rattled, as it unveiled major leadership changes and another sharp downgrade to its 2025 financial outlook. The company slashed its full-year sales growth guidance to 8%-14%, down from the previously expected 13%-21%. Operating profit growth was also revised lower, now projected at 10%-16% compared to May's forecast of 16%-24%. The revised outlook sent a strong signal that Novo is bracing for a more challenging year ahead. A big part of the pressure comes from its obesity blockbuster, Wegovy. In its update, Novo pointed to several headwinds weighing on U.S. sales, including the continued rise of compounded GLP-1 knockoffs, slower-than-expected market expansion, and increasing competition. These challenges have clouded the outlook for one of Novo's key growth drivers, sparking concerns about whether the company can maintain its dominance in the rapidly growing weight-loss market. Adding to the uncertainty, Novo also announced a leadership shake-up. Maziar Mike Doustdar, the current EVP of international operations, will take over as CEO on Aug. 7, succeeding Lars Fruergaard Jørgensen, whose surprise resignation was announced in May. The transition comes at a pivotal moment, with the company under pressure to protect market share and reignite growth amid shifting dynamics in the obesity drug landscape. What Do Analysts Think About Novo Nordisk Stock? Despite all the swirling uncertainty, there's still a hint of optimism in the air. With Novo Nordisk set to unveil its Q2 earnings on Aug. 6 and a new CEO stepping in shortly after, Wall Street hasn't lost faith, with analysts leaning cautiously bullish, giving the stock a consensus rating of 'Moderate Buy' overall. Of the 19 analysts offering recommendations, seven advise a 'Strong Buy,' nine suggest a 'Hold,' one advocates a 'Moderate Sell,' and the remaining two maintain a 'Strong Sell.' NVO's average analyst price target of $71.75 suggests 47% potential upside from current levels. However, the Street-high target of $112 implies that shares can rally as much as 129.5% from current price levels. On the date of publication, Anushka Mukherji did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
an hour ago
- Yahoo
Talking therapy for depression and anxiety ‘less effective for young adults'
NHS talking therapies for depression and anxiety appear to be less effective for young adults, according to new analysis. Younger people may find it 'harder to navigate services set up for adults' – with attendance to therapy sessions hampered by stressful life events in the late teens and early 20s, experts suggest. Researchers warned there is an 'urgent need' to ensure the best possible mental healthcare for people aged 16-25 amid rising rates of mental health conditions. NHS talking therapy for conditions like anxiety and depression can include cognitive behavioural therapy (CBT), counselling, and guided self-help using workbooks or online courses. To explore ways in which services could be tailored to younger people, experts from University College London (UCL) analysed data from 1.5 million people who had attended NHS talking therapies in England between 2015 and 2019, including more than 309,758 people aged between 16 and 24. Using self-reported scores from questionnaires taken before and after treatment, researchers found younger adults were 25% less likely to meet the threshold for reliable recovery after having talking therapy. They were also 17% less likely to meet criteria for reliable improvement when compared to those aged 25-65. Professor Argyris Stringaris, of UCL psychiatry, suggested people aged 16-24 may find it harder to regularly attend therapy sessions. He said: 'Young people may find it harder to navigate services which have been set up for adults, and are more likely to miss sessions or stop attending altogether. 'Additionally, the late teens and early 20s are a point of transition for many people, which can involve plenty of stressful life events and changes that may make it more difficult to consistently attend. 'Working together with young people should help optimise the content of treatment and the ways in which it is delivered. 'Finally, young people may suffer from depression and anxiety problems that may differ somehow in their causes from those affecting adults; early onset depression could have different causes and may require different approaches to treatment. This is an area that requires a lot of new basic and clinical research.' Researchers said the findings, published in Lancet Psychiatry, suggest future studies should consider tailoring mental health services to young people. Dr Rob Saunders, of UCL psychology and language sciences, said: 'Talking therapy is an effective treatment for depression and anxiety disorders, and particularly tends to be preferred to pharmacological treatment by younger adults. 'Our analysis shows that talking therapies offered by the NHS are effective for younger adults, but as they are more effective for working-age adults, we believe there is work to be done to improve services for young adults. 'Rates of depression and anxiety in young adults are rising, so there is an urgent need to ensure we are offering them the best possible mental health care.' The latest Adult Psychiatric Morbidity Survey, published in June, found more than a quarter of people aged 16-24 reported having so-called 'common mental health conditions', which include generalised anxiety disorder, depressive episodes, phobias, obsessive compulsive disorder (OCD) and panic disorder. The figure was up from 17.5% in 2007. An NHS spokesperson said: 'This study finds talking therapy is still helpful for young people and so we would urge them to come forward for care with our world-leading talking therapies service which provides evidence-based mental health support to more than a million people a year, with nine in 10 patients receiving support within six weeks.' Olly Parker, head of external affairs and research at the charity YoungMinds, said: 'Growing up today is incredibly tough. 'Many young people are experiencing multiple pressures which impact their mental health, including poverty, inequality, intense academic pressure, and the online world. It's no wonder so many are struggling. 'We know many young people face long waits for mental health support and become more unwell while waiting, which can lead to needing more urgent care. We need to take an evidence-led approach to getting support right, ensuring young people are involved in choosing the treatments that work best for them. 'These findings must serve as another wake-up call to Government that urgent action is needed to reverse the decline in young people's mental health. This looks like a cross-government response that asks why so many young people are struggling, with radical solutions to address these root causes of poor mental health.'
Yahoo
2 hours ago
- Yahoo
Crackdown on cosmetic surgery ‘cowboys' over botched Brazilian butt lifts and Botox
Ministers want to clamp down on 'cowboy' cosmetic procedures including Botox and Brazilian butt lifts after a string of horror incidents which left customers dead or with catastrophic damage. Officials said the industry had been blighted by 'dodgy practitioners and procedures', with some patients 'maimed' during botched treatments. It follows the case of mother-of-five, Alice Webb, who is thought to be the first person to have died following a non-surgical liquid Brazilian butt lift (BBL) procedure at a UK clinic. The Department of Health and Social Care (DHSC) has proposed new restrictions on who can access and provide treatments in a bid to protect people from 'rogue operators' with no medical training who often provide 'invasive' procedures in homes, hotels and pop-up clinics. The move should also reduce the cost imposed upon the NHS to fix botched procedures, DHSC added. Tim Mitchell, president of the Royal College of Surgeons of England, hailed the proposals as an 'important first step forward for patient safety.' Health minister Karin Smyth said: 'The cosmetics industry has been plagued by a Wild West of dodgy practitioners and procedures. 'There are countless horror stories of cosmetic cowboys causing serious, catastrophic damage.' She said the government would take action too 'root out cowboys' and support 'honest and competent practitioners.' 'This isn't about stopping anyone from getting treatments – it's about preventing rogue operators from exploiting people at the expense of their safety and keeping people safe,' Ms Smyth added. 'We're giving them peace of mind and reducing the cost to the NHS of fixing botched procedures.' The government's proposals include: Only allowing healthy workers who are 'suitably qualified' to be able to deliver high-risk procedures such as (BBLs) Ensuring providers are regulated by the health regulator, the Care Quality Commission. Slapping sanctions and finanial penalties on those who break rules on high-risk procedures Ensuring clinics offering Botox and fillers are licensed Introducing age restrictions to prevent children from trying to follow 'dangerous beauty trends on social media' The timeline for the introduction and completion of these measures was not stated. But the DHSC said it will launch a consultation next year seeking views on the range of procedures which should be covered in the new restrictions. Last month, the Chartered Trading Standards Institute warned that fat injections, BBLs, Botox and fillers are being offered by untrained people in places such as public toilets. Before the proposed regulations come into force, the government has urged people seeking cosmetic procedures to ask for the provider's qualifications and insurance, and to be wary of 'suspiciously cheap' offers. Health officials launched an investigation after a number of people had reactions to Botox injections earlier this year. Professor David Sines CBE, the chair and registrar of Joint Council for Cosmetic Practitioners (JCCP), said the move will 'protect the public from untrained and inexperienced operators and it will save the NHS a considerable amount of time and money putting right the harm done through botched procedures.' The statement added the need for the new measures had become increasingly clear in recent years with the 'explosion of high street outlets offering high-risk procedures delivered by people with limited clinical knowledge and training.' He warned this has led to long-term health complications and, in some cases, has led to patient deaths. Mr Mitchell suggested the government must go further on liquid Brazilian Butt Lifts, which the RCS said the procedure should only be performed by a Cosmetic Surgery Board-certified surgeon. The surgeon warned that the procedure needs medical oversight to prevent serious complications and said that while the government's plans will improve the regulation of non-surgical interventions, it must also urgently improve the regulation of surgical procedures. Millie Kendall, chief executive of the British Beauty Council, said: 'Any measures that increase protection for the general public and professionalise the industry will help instil confidence as well as helping to prevent the normalisation of horror stories that have become synonymous with our sector.'
